

Maladaptive TGF- β signals to the alveolar epithelium drive fibrosis after COVID-19 infection

Changfu Yao^{1,*}, Tanyalak Parimon^{1,*}, Milena S. Espindola¹, Miriam S. Hohmann¹, Bindu Konda¹, Cory M. Hogaboam^{1,*}, Barry R. Stripp^{1,*}, Peter Chen^{1,*}

¹Women's Guild Lung Institute, Cedars-Sinai Medical Center; Los Angeles, CA 90048

*Equal Contribution

Correspondence:

Cory Hogaboam, PhD

127 S San Vicente Blvd; A9315

Los Angeles, CA 90048

Email: Cory.Hogaboam@cshs.org

Barry R. Stripp, PhD

127 S San Vicente Blvd; A9317

Los Angeles, CA 90048

Email: Barry.Stripp@cshs.org

Peter Chen, MD

127 S San Vicente Blvd; A9401

Los Angeles, CA 90048

Email: Peter.Chen@cshs.org

Contribution: Concept and design of work, data analysis, and data interpretation: CY, TP, MSE, MSH, CMH, BRS, PC. Data acquisition: CY, BK. Draft and revision: CY, TP, MSE, MSH, CMH, BRS, PC.

Funding: This study was supported by funding from the NIH [KL2TR001882 (CY), K08HL141590 (TP), R01HL159160 (BRS), R01HL137076 (PC), R01HL155759 (PC), and R01HL159953 (PC)], Parker B. Francis Foundation Fellowship (CY), Cedars-Sinai Medical Center (CMH) and the Plum Foundation (PC).

Running Heading: Lung fibrosis from COVID-19 infection

Subject Category List: 9.23 Interstitial Lung Disease

Word Count: 967

Conflicts of interest: The authors have no conflicts relevant to this submission.

This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>). For reprints please contact Diane Gern (dgern@thoracic.org).

To the Editor:

Many people with COVID-19 show persistent symptoms after clearance of the infection. The extent of post-acute sequelae of SARS-CoV-2 infection (PASC; aka Long COVID) is still being characterized and a focus of current research. However, one clear manifestation of PASC is chronic lung fibrosis, particularly among those recovering from severe COVID-19 (1).

Studies of fibrotic lung disease as a sequelae of COVID-19, herein referred to as “PASC lung fibrosis”, have been limited. A recent study found that up to 11% of patients hospitalized with COVID-19 had persistent lung abnormalities identified by CT scan (2). Autopsy studies have identified early fibrogenic signals in the lungs that appear to represent a trajectory of dysregulated lung repair (3, 4). However, the mechanism(s) driving PASC lung fibrosis (characterized by non-specific interstitial pneumonia (NSIP)-like features (1)) cannot be fully elucidated by autopsy studies, since acute lethality from COVID-19 is typically from acute respiratory distress syndrome (ARDS) with findings of diffuse alveolar damage (DAD) (3, 5).

To investigate potential mechanisms driving PASC lung fibrosis, we performed single-cell RNA sequencing (scRNA-seq) of lung explants and compared our data to other scRNA-seq datasets prepared from control and idiopathic pulmonary fibrosis (IPF) lung explants (**Figure 1**). All code and methods are available at <https://github.com/ivonyao/PASC>. We identified a decrease in the alveolar type 2 (AT2) cell fraction in fibrotic conditions, with compensatory increases in representation of other epithelial cell types (**Figure 1B**). Moreover, we found a decrease in the FABP4+ (alveolar) macrophage population in PASC conditions (**Figure 1C – 1D**).

We compared the module scores of the top dysregulated pathways between conditions in all major lung epithelial populations and found a similar pattern of upregulation among several

profibrotic pathways between all epithelial cell types of both PASC lung fibrosis and IPF, compared to controls (**Figure 2A**). We and others have observed that transitional cells (KRT8+, KRT17+, KRT5-) are increased in lung explanted from those undergoing transplantation for chronic lung dysfunction after SARS-CoV-2 infection (1). These transitional cells have gained attention as they are found in both ARDS and IPF (5, 6). As such, we focused our attention to the transitional cell population and observed striking similarities between PASC and IPF in the upregulation of fibrogenic signals such as TGF- β , p53, and cellular senescence (**Figure 2A**). Our analyses also revealed that transitional cells having a cellular senescence signature, absent in control lungs but progressively increasing from PASC to IPF conditions, suggest that cellular senescence may be a prerequisite for fibrosis. Accordingly, transitional cells observed in lungs of those that succumbed to COVID-19 and non-COVID-19 ARDS, where there is a lack of organized fibrosis, lacked signatures of cellular senescence.

Dysregulated TGF- β signaling affects the immunologic response to acute SARS-CoV-2 infection and correlates with the severity of COVID-19 (7, 8). The important role of TGF- β in driving lung fibrosis is well documented (1), and considering the association between the development of PASC lung fibrosis and severity of COVID-19, we further evaluated the magnitude of TGF- β signaling in transitional cells observed in patients with PASC (**Figure 2A**). We created an inferred communication network of the aggregate TGF- β signals to understand potential intercellular communications driving lung fibrosis (**Figure 2B**). In all conditions, TGF- β signals originated and emanated from macrophages. Interestingly, the target of TGF- β signals switched from solely being plasmacytoid dendritic cells (pDCs) in controls to an equal distribution between pDCs and transitional cells in IPF, and largely concentrated on the transitional cell population in PASC lung fibrosis. Loss of the FABP4+ macrophages (**Figure 1D**) appears to be the primary driver of reduced TGF- β signaling between macrophage and pDCs (**Figure 2C**). Moreover, the probability

of these putative TGF- β signaling network between macrophage subpopulations and transitional cells was highest in PASC lung fibrosis compared to IPF (**Figure 2C**).

Monocyte-derived macrophages (Mo-AMs) are pro-fibrotic and a key source of the TGF- β that drives lung fibrosis (9, 10). Notably, Mo-AMs with a prominent TGF- β signature accumulate in the lungs of those that succumb to COVID-19 ARDS (4). Together with our findings in PASC lung fibrosis (**Figure 2A – 2C**), these data suggest TGF- β expression by macrophages target transitional cells to promote fibrosis. Indeed, TGF- β has a biphasic action in the regeneration of the alveolar epithelium, representing an early event required for AT2 cells to assume a transitional cell state, yet blocks differentiation into AT1 cells (5). Accordingly, activated macrophages may play a central role in providing the TGF- β stimulus to forestall wound healing and promote fibroproliferation through interrupting AT2 to AT1 differentiation with concomitant accumulation of profibrotic transitional cells.

Herein, we provide a focused evaluation of epithelial and immune cells in PASC lung fibrosis and identified a putative maladaptive communication network that interlink the profibrotic macrophage with the activation and/or development of transitional cells in lung fibrosis. This analysis is a first step in understanding the mechanisms of PASC lung fibrosis and future directions would expand into other cellular compartments (e.g., mesenchymal cells). We propose a concept where PASC lung fibrosis is localized along a spectrum of fibrotic lung diseases with one end anchored by a resolving fibroproliferation present in ARDS and the other end anchored by IPF (**Figure 2D**). The accelerated appearance of PASC lung fibrosis from an overwhelming viral-mediated inflammatory stimulus results in an NSIP-like pathology. In contrast, the development of IPF appears to involve a more protracted timeline, which could contribute to a very different histopathological finding (i.e., usual interstitial pneumonitis). Only time will reveal whether SARS-CoV-2 infections produce a

progressive destruction of the lungs such as in IPF. However, emerging research, including what we present here, demonstrates the underlying pathogenic mechanisms driving fibroproliferation in PASC lung fibrosis have common features with IPF. Hence, studies into PASC lung fibrosis could provide novel insights into the maladaptive mechanisms that have broader implications across many types of chronic and progressive interstitial lung fibrosis.

Figure legend

Figure 1. Cell type identification of epithelial cells and immune cells in scRNA-seq evaluation of lungs from control, PASC lung fibrosis, and IPF. A) We performed single cell RNA sequencing (scRNA-seq) of lung explants from five patients with PASC lung fibrosis undergoing lung transplantation, four of which had samples from the apical and basal segments of the lung independently processed for cell capture and barcoding providing a total of 9 scRNA-seq samples. These data were merged with scRNA-seq data from GSE146981 and GSE135893 that contain lungs from control (n = 21) and IPF patients (n = 30) using the Harmony R package for batch correction and Seurat R package for analysis. As part of our quality control, we removed cells that were doublets, low quality, stressed, and had mitochondrial genes <10%, which yielded 38321 control, 40324 PASC, and 62365 IPF cells. All the sequencing data along with their associated metadata have been deposited in the GEO database under accession code GSE224955. **B – D)** UMAP and frequency of **B)** epithelial cell clusters, **C)** immune cell clusters, and **D)** macrophage populations.

Figure 2. Cells in PASC lung fibrosis develop a profibrotic signaling networks like that in IPF. A) Differentially expressed genes (DEGs) were determined within each epithelial cell type between each condition (control, PASC, IPF). Ingenuity Pathway Analysis (IPA) was used to identify the canonical pathways that were represented by the DEGs between conditions, and the top pathways that were common to all evaluations were used to generate a module score. Except for those that are designed as “ns” (non-significant), all comparisons were significant by a Kruskal-Wallis test with a FDR < 0.05 (nearly all were highly significant with FDR < 0.0001). **B – C)** Inferred communication network of all ligand-receptor interactions for the TGF- β signaling pathway was determined. Using CellChat™, we measured weighted-directed networks, including out-degree, in-degree, flow betweenness and information centrality, to respectively identify dominant senders, receivers, mediators, and influencers for the intercellular communications. In a weighted directed

network with the weights as the computed communication probabilities, the outdegree, computed as the sum of communication probabilities of the outgoing signaling from a cell group, and the in-degree, computed as the sum of the communication probabilities of the incoming signaling to a cell group, can be used to identify the dominant cell senders and receivers of signaling networks, respectively. **B)** The chord diagram visually represents inferred cell-cell communication network of TGF- β pathway, and the heatmap visually represents the data network centrality scores, dominant senders, receivers, mediators, and influencers in the intercellular communication network by computing several network centrality measures. **C)** The probability of the communication score of ligand-receptor pairs (TGFB1 with TGFBR1 and TGFBR2) from sender cell groups to receiver cell groups. **D)** Schematic of our proposed concept for a continuum of lung fibrosis.

Acknowledgements

We thank the Biobank Core at Cedars-Sinai Medical Center for their help in these studies.

References

1. Parimon T, Espindola M, Marchevsky A, Rampolla R, Chen P, Hogaboam CM. Potential Mechanisms for Lung Fibrosis Associated with COVID-19 Infection. *QJM* 2022; In Press.
2. Stewart I, Jacob J, George PM, Molyneaux PL, Porter JC, Allen RJ, Aslani S, Baillie JK, Barratt SL, Beirne P, Bianchi SM, Blaikley JF, Chalmers JD, Chambers RC, Chadhuri N, Coleman C, Collier G, Denneny EK, Docherty A, Elneima O, Evans RA, Fabbri L, Gibbons MA, Gleeson FV, Gooptu B, Greening NJ, Guio BG, Hall IP, Hanley NA, Harris V, Harrison EM, Heightman M, Hillman TE, Horsley A, Houchen-Wolloff L, Jarrold I, Johnson SR, Jones MG, Khan F, Lawson R, Leavy O, Lone N, Marks M, McAuley H, Mehta P, Parekh D, Hanley KP, Plate M, Pearl J, Poinasamy K, Quint JK, Raman B, Richardson M, Rivera-Ortega P, Saunders L, Saunders R, Semple MG, Sereno M, Shikotra A, Simpson AJ, Singapuri A, Smith DJF, Spears M, Spencer LG, Stanel S, Thickett DR, Thompson AAR, Thorpe M, Walsh SLF, Walker S, Weatherley ND, Weeks ME, Wild JM, Wootton DG, Brightling CE, Ho LP, Wain LV, Jenkins GR. Residual Lung Abnormalities after COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID-19 Study. *Am J Respir Crit Care Med* 2023; 207: 693-703.
3. Kamp JC, Werlein C, Plucinski EKJ, Neubert L, Welte T, Lee PD, Tafforeau P, Walsh C, Kuehnel MP, Schuppan D, Hoepfer MM, Jonigk DD, Ackermann M. Novel Insight into Pulmonary Fibrosis and Long COVID. *Am J Respir Crit Care Med* 2023; 207: 1105-1107.
4. Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL, Pascual-Reguant A, Mothes R, Bulow RD, Schulze J, Leipold AM, Djurdjaj S, Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Bassler K, Conrad C, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst D, Deutsche C-OI, Hippenstiel S, Hocke A, Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault C, Witzenrath M,

- Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, Schultze JL, Radbruch H, Ochs M, Eils R, Muller-Redetzky H, Hauser AE, Luecken MD, Theis FJ, Conrad C, Wolff T, Boor P, Selbach M, Saliba AE, Sander LE. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. *Cell* 2021; 184: 6243-6261 e6227.
5. Ting C, Aspal M, Vaishampayan N, Huang SK, Riemondy KA, Wang F, Farver C, Zemans RL. Fatal COVID-19 and Non-COVID-19 Acute Respiratory Distress Syndrome Is Associated with Incomplete Alveolar Type 1 Epithelial Cell Differentiation from the Transitional State without Fibrosis. *Am J Pathol* 2022; 192: 454-467.
6. Jiang P, Gil de Rubio R, Hrycaj SM, Gurczynski SJ, Riemondy KA, Moore BB, Omary MB, Ridge KM, Zemans RL. Ineffectual Type 2-to-Type 1 Alveolar Epithelial Cell Differentiation in Idiopathic Pulmonary Fibrosis: Persistence of the KRT8(hi) Transitional State. *Am J Respir Crit Care Med* 2020; 201: 1443-1447.
7. Ferreira-Gomes M, Kruglov A, Durek P, Heinrich F, Tizian C, Heinz GA, Pascual-Reguant A, Du W, Mothes R, Fan C, Frischbutter S, Habenicht K, Budzinski L, Ninnemann J, Jani PK, Guerra GM, Lehmann K, Matz M, Ostendorf L, Heiberger L, Chang HD, Bauherr S, Maurer M, Schonrich G, Raftery M, Kallinich T, Mall MA, Angermair S, Treskatsch S, Dorner T, Corman VM, Diefenbach A, Volk HD, Elezkurtaj S, Winkler TH, Dong J, Hauser AE, Radbruch H, Witkowski M, Melchers F, Radbruch A, Mashreghi MF. SARS-CoV-2 in severe COVID-19 induces a TGF-beta-dominated chronic immune response that does not target itself. *Nat Commun* 2021; 12: 1961.
8. Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, Frischbutter S, Angermair S, Hohnstein T, Mattiola I, Nawrath P, McEwen S, Zocche S, Viviano E, Heinz GA, Maurer M, Kolsch U, Chua RL, Aschman T, Meisel C, Radke J, Sawitzki B, Roehmel J, Allers K, Moos V, Schneider T, Hanitsch L, Mall MA, Conrad C, Radbruch H, Duerr CU, Trapani JA, Marcenaro E, Kallinich T, Corman VM, Kurth F, Sander LE, Drosten C, Treskatsch S, Durek P, Kruglov A, Radbruch A, Mashreghi MF, Diefenbach

- A. Untimely TGFbeta responses in COVID-19 limit antiviral functions of NK cells. *Nature* 2021; 600: 295-301.
9. Misharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie-Pimentel AC, Chen CI, Anekalla KR, Joshi N, Williams KJN, Abdala-Valencia H, Yacoub TJ, Chi M, Chiu S, Gonzalez-Gonzalez FJ, Gates K, Lam AP, Nicholson TT, Homan PJ, Soberanes S, Dominguez S, Morgan VK, Saber R, Shaffer A, Hinchcliff M, Marshall SA, Bharat A, Berdnikovs S, Bhorade SM, Bartom ET, Morimoto RI, Balch WE, Sznajder JI, Chandel NS, Mutlu GM, Jain M, Gottardi CJ, Singer BD, Ridge KM, Bagheri N, Shilatifard A, Budinger GRS, Perlman H. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. *J Exp Med* 2017; 214: 2387-2404.
10. Singh A, Chakraborty S, Wong SW, Hefner NA, Stuart A, Qadir AS, Mukhopadhyay A, Bachmaier K, Shin JW, Rehman J, Malik AB. Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis. *Proc Natl Acad Sci U S A* 2022; 119: e2121098119.







Figure 1



D

Clinical Phenotype	Normal	→ ARDS	→ PASC lung fibrosis	→ IPF
Histology	Normal	DAD	NSIP-like	UIP
Fibrosis Continuum	Normal	Post-inflammatory fibroproliferation	Accelerated Fibrosis	Protracted Fibrosis
Time After Injury	n/a	Weeks	Months	Years
Cellular Senescence	-	-	++	+++
TGF-β Signaling	-	+	++++	++
Transitional Cells	-	+	+++	++++

Figure 2